Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sana Biotechnology, Inc.

2.93
+0.275010.36%
Post-market: 2.77-0.1600-5.46%19:59 EDT
Volume:2.99M
Turnover:8.27M
Market Cap:654.18M
PE:-2.12
High:2.94
Open:2.83
Low:2.62
Close:2.66
Loading ...

Sana Biotechnology Shares Almost Triple in After Hours Trading Following 'Positive' Diabetes Study Results

MT Newswires Live
·
08 Jan

Sana Biotechnology Shares Spike Following Successful Transplantation

Dow Jones
·
08 Jan

BRIEF-Sana Biotechnology Announces Positive Clinical Results From Type 1 Diabetes Study Of Islet Cell Transplantation Without Immunosuppression

Reuters
·
08 Jan

Sana Biotechnology up 285% afterhours following type 1 diabetes study data

TIPRANKS
·
08 Jan

Sana Biotechnology Reports 'Positive' Results From Diabetes Study of Islet Cell Transplantation; Shares Surge

MT Newswires Live
·
08 Jan

Sana Biotechnology announces initial results from type 1 diabetes study

TIPRANKS
·
08 Jan

Sana Biotechnology Inc -Mri Shows Signals Consistent With Graft Survival 28 Days After Transplantation

THOMSON REUTERS
·
08 Jan

Sana Biotechnology Announces Positive Clinical Results From Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

THOMSON REUTERS
·
08 Jan

Sana Biotechnology Inc - Study Identifies No Safety Issues, Hip-Modified Islet Cells Evade Immune Responses

THOMSON REUTERS
·
08 Jan

Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

GlobeNewswire
·
08 Jan

BofA Securities Adjusts Price Target on Sana Biotechnology to $7 From $8, Maintains Buy Rating

MT Newswires Live
·
08 Jan

Sana Biotechnology Inc : Bofa Global Research Cuts Price Objective to $7 From $8

THOMSON REUTERS
·
07 Jan

Sana Biotechnology Drops To US$1.63, Yet Insiders May Have Sold Too Early

Simply Wall St.
·
24 Dec 2024

Sana Biotechnology's SC291 Gets FDA Fast Track Designation for Systemic Lupus Erythematosus

MT Newswires Live
·
02 Dec 2024

Sana Biotechnology Gets FDA Fast Track Designation for SC291 Cell Therapy

Dow Jones
·
02 Dec 2024

Sana Biotechnology Inc - Expect to Report Initial Clinical Data in 2025 in Gleam Trial for Sc291 in B-Cell Mediated Autoimmune Diseases

THOMSON REUTERS
·
02 Dec 2024